We narrowed to 82,911 results for: ELL

#228902-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine (#228902). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine plasmid DNA. CAG-driven, Cre dependent expression of a peripherally restricted DREADD. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Kang et al Cell. 2024 Dec 26;187(26):7433-7449.e20.

Oct. 8, 2025

Academic Institutions and Nonprofits only

#169942

Knockout library targeting ubiquitin ligases, deubiquitinases, and control genes.

Benjamin Ebert

Slabicki et al Nature. 2020 Sep;585(7824):293-297. doi:

Sept. 9, 2021

Academic Institutions and Nonprofits only

#160129

Targets mouse metabolic genes and includes most metabolic enzymes and transporters.

Kivanc Birsoy

Zhu et al Cell Metab. 2020 Oct 28. pii: S1550-4131

Nov. 10, 2020

Academic Institutions and Nonprofits only

#122131

Increases transcriptional repression of genes encoding transcription factors in combination with dCas9 repression systems, such as the dCas9-KRAB system.

Stanley Qi

Liu et al Cell Stem Cell. 2018 Sep 28. pii: S1934-

April 25, 2019

Academic Institutions and Nonprofits only

#123334

Designed for genomic deletion screening of transcription factors by targeting the DNA binding domains.

Christopher Vakoc

Huang et al Genes Dev. 2018 Jul 1;32(13-14):915-928.

May 2, 2019

Academic Institutions and Nonprofits only

#216133

Library of intron-targeting sgRNAs for pooled tagging of proteins with GFP or other protein tags at their endogenous genomic locus using an intron tagging approach.

Stefan Kubicek

Reicher et al Nat Cell Biol. 2024 May;26(5):745-756. d

April 19, 2024

Academic Institutions and Nonprofits only

#183519-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (#183519). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE plasmid DNA. CaMKIIa-driven expression of ChRmine-oScarlet-KV 2.1. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Kishi et al Cell. 2022 Feb 17;185(4):672-689.e23. do

Dec. 18, 2024

Academic Institutions and Nonprofits only

#179460-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-DIO-JEDI-2P-WPRE (#179460). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-JEDI-2P-WPRE plasmid DNA. EF1a-driven, Cre-dependent expression of voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Aug. 22, 2022

Academic Institutions and Nonprofits only

#179459-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-DIO-JEDI-2P-Kv-WPRE (#179459). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-JEDI-2P-Kv-WPRE plasmid DNA. EF1a-driven, Cre-dependent soma and AIS-localized expression of voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Aug. 23, 2022

Academic Institutions and Nonprofits only

#237473

Enables high-throughput identification of frame-preserving exons that influence transcriptional phenotypes, building on the CHyMErA system (Nature Biotechnology, 2020; PMID: 32249828).

Thomas Gonatopoulos-Pournatzis

Kumari et al Nat Commun. 2026 Feb 3;17(1):1218. doi:

Oct. 28, 2025

Academic Institutions and Nonprofits only

#209734

CHyMErA Cas12a Nuclease Optimization hgRNA Libraries allows assessment and comparison of the efficacy of different LbCas12a nucleases in the context of the Cas9-Cas12a CHyMErA system.

Thomas Gonatopoulos-Pournatzis

Xiao et al Mol Cell. 2024 Jul 11;84(13):2553-2572.e

June 20, 2024

Academic Institutions and Nonprofits only

#209735

CHyMErA Cas12a Nuclease Optimization hgRNA Libraries allows assessment and comparison of the efficacy of different AsCas12a nucleases in the context of the Cas9-Cas12a CHyMErA system.

Thomas Gonatopoulos-Pournatzis

Xiao et al Mol Cell. 2024 Jul 11;84(13):2553-2572.e

June 20, 2024

Academic Institutions and Nonprofits only

#229136

The EGFP_miSFIT_Lineage_BC_lib library is a transcribed lineage barcoding vector library.

Peter Zandstra

Michaels et al Cell Syst. 2024 Dec 18;15(12):1245-1263.

Oct. 24, 2025

Academic Institutions and Nonprofits only

#67989

Knockout library targeting 18,010 human genes. gRNAs were improved using a new design pipeline and improved gRNA scaffold.

Kosuke Yusa

Tzelepis et al Cell Rep. 2016 Oct 18;17(4):1193-1205. d

Oct. 14, 2016

Academic Institutions and Nonprofits only

#67988

Knockout library targeting 18,424 mouse genes. gRNAs were improved using a new design pipeline and improved gRNA scaffold.

Kosuke Yusa

Tzelepis et al Cell Rep. 2016 Oct 18;17(4):1193-1205. d

Oct. 14, 2016

Academic Institutions and Nonprofits only

#213859-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_GCaMP6f (#213859). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213947-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_GCaMP6f (#213947). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213917-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213833-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213918-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_jGCaMP8m (#213918). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_jGCaMP8m plasmid DNA. Expression of jGCaMP8m under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only